Evidence map›Paper›PMID 34049806›Full record

ReviewHeart, lung & circulation2021

Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue.

Elias Sanidas, Charalampos Grassos, Dimitrios Papadopoulos, Maria Velliou, John Barbetseas

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart, lung & circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Elias SanidasDepartment of Cardiology, LAIKO General Hospital, Athens, Greece. Electronic address: easanidas@yahoo.gr.
Charalampos GrassosDepartment of Cardiology, KAT General Hospital, Athens, Greece.
Dimitrios PapadopoulosDepartment of Cardiology, LAIKO General Hospital, Athens, Greece.
Maria VelliouDepartment of Cardiology, LAIKO General Hospital, Athens, Greece.
John BarbetseasDepartment of Cardiology, LAIKO General Hospital, Athens, Greece.
Laiko General Hospital of Athens · GRGeneral Hospital of Attica · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected disease. This review summarises current aspects and recommendations regarding the use of thromboprophylaxis for PE in patients with COVID-19.

Indexed as

COVID-19Pulmonary EmbolismVenous ThromboembolismAnticoagulantsHumansSARS-CoV-2AnticoagulantsCoagulopathyCOVID-19Pulmonary embolismThromboprophylaxis

Identifiers

PMID34049806
PMCPMC8114761
OpenAlexW3160048883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.